Learn to calculate fixed asset depreciation in Excel using methods like straight-line, sum of the years' digits, and more for ...
The company claims it’s a cheaper and more environmentally friendly alternative to land-based centers. The company claims it’s a cheaper and more environmentally friendly alternative to land-based ...
New simulator and computational tools generate realistic ‘virtual tissues’ and map cell-to-cell ‘conversations’ from spatial transcriptomics data, potentially accelerating AI-driven discoveries in ...
Scientists at KAIST have found a way to turn a tumor’s own immune cells into powerful cancer fighters—right inside the body. Tumors are packed with macrophages, immune cells that should attack cancer ...
Scientists can peer into cells to get a limited view of their activity using microscopes and other tools. However, cells and the molecular events within them are dynamic, and developmental processes, ...
A Texas teenager was rescued by her father after she was forced into a truck at knifepoint on Christmas Day, police said. Patrol deputies with the Montgomery County Sheriff's Office were called to an ...
A Texas teenager was rescued by her father after she was forced into a truck at knifepoint on Christmas Day, police said. Patrol deputies with the Montgomery County Sheriff's Office were called to an ...
The US government is beginning to grow cautious of AI data centers (AIDCs) because of their enormous pressure on power grids. In facing the hard limits of energy resources, policymakers will be forced ...
At its annual Ecosystem Day on December 12, Hithium Energy Storage signaled a strategic improvement beyond conventional four-hour batteries, positioning long-duration storage as both a grid asset and ...
The ongoing phase I/II clinical trial is evaluating the safety, tolerability and early efficacy signals of Aleta’s first-in-class biologic CAR T-cell engager, ALETA-001 Preliminary findings include a ...
Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason ...
-- Results from the Phase 1/2 Trial are a Foundation for the Ongoing Pivotal Study of Soficabtagene Geleucel for R/R T-Cell ALL/ LBL in Pediatric and Adult Patients ST. LOUIS, Mo., Dec. 05, 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results